Cellular localization of immunoglobulin within human maglignant melanomata. by Lewis, M. G. et al.
Br. J. Cancer (1976) 33, 260
CELLULAR LOCALIZATION OF IMMUNOGLOBULIN
WITHIN HUMAN MALIGNANT MELANOMATA
M. G. LEWIS*, J. NV. PROCTOR*, D. Al. P. THOi\ISONt, G. ROWVDEN*
AND T. AI. PHILLIPS*
From the *McGill University Cantcer Research Unit, .llcIntyre Jlledical Sciences Building,
3655 Drummond Street, Mlontreal, P.Q., Canada H30 1 Y6, and tM3lcGill University
Medical Clinic, Montreal General Hospital, Mllontreal, P.Q., Cavnada
Received 18 August 1975 Accepted 2 December 1975
Summary.-The presence of antibody in patients with malignant melanoma is
well established if one examines the serum. In this report we have attempted to
identify antibody within solid tumours showing that they are rarely present in
any appreciable quantity on the surface of tumour cells but can be seen frequently
on a number of different types of host cell within the tumours.
This is discussed in the light of the role of antibody in the circulation and the
possibility of antibody behaving as a blocking factor in vivo.
ANTI-TUMOUR antibodies have been re-
ported in the serum of patients with a
wide variety ofmalignancies (Nairn, 1974;
Mastrangelo, Laucius and Outzen, 1974). A
definitiverole,however,hasnot been estab-
lished for such antibodies, although it
has beenpostulated thatthey might consti-
tute a powerful mechanism for protecting
the host from blood-borne metastatic
spread (Lewis, McCloy and Black, 1973b;
Bodurtha et al., 1975), since anti-tumour
antibodies disappear from the serum of
melanoma patients prior to the clinical
appearance of distant metastases. Other
workers have postulated, on the results of
in vitro tests, that they block cell-mediated
immunity (Hellstr6m et al., 1971; Bansal
and Sj6gren, 1971). There have also
been a number of further reports on
the elution of anti-tumour antibodies
from whole tumours (Sj6gren et al.,
1972), in which such antibody was as-
sumed to have been bound to the mem-
branes of the tumour cells (Witz, 1973;
Romsdahl and Cox, 1971) and possibly,
therefore, to act as a blocking inechanism
against cell mediated immunity. Host
cells have been noted in varying numbers
within tumours (Sarma, 1.970; Ritchers
and Kaspersky, 1975) and small lympho-
cytes, plasma cells and macrophages have
all been described in such reports (Roberts
et al., 1973; Little, 1972). The various
conclusions drawn from these publications
taken together constitute a controversial
issue. Attempts to define the location
of antibody within tumours, particularly
in terms of whether it is present on the
surface of tumour cells or host cells, or
merely diffused throughout extracellular
spaces, could throw considerable light
on the relative importance of anti-
tumour antibody with regard to its role
as a protective or a facilitating immune
mechanism in viro.
This communication presents data
on the presence ofantibody on the surface
of and within host cells, particularly small
lymphocytes and plasma cells, and demon-
strates that antibody is rarely detected
on the surface of tumour cells.
These observations are discussed in
terms of the possibility that tumour
cells do not act as a sponge by absorbing
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antibody from the circulation, and further
that antibody by itself is unlikely to
act as a blocking agent at the target cell
level in vivo.
MATERIALS AND METHODS
Sera and tumour cells were obtained
from 37 malignant melanoma patients, and
single-cell suspensions of tumour prepared
by mechanical dispersion without the aid
of enzymes (Lewis et al., 1969). These
cells were tested by the direct immuno-
fluorescence technique and after prior incu-
bation with autologous serum, by the
indirect technique, using a fluorescein-con-
jugated sheep anti-human gammaglobulin
preparation (Welleome Research Labs.,
Beckenham, England, BR3 3BS).
Both ofthe fluorescent techniques (Nairn,
1969; Phillips and Lewis, 1970), the fluores-
cent index used for semi-quantitation (Klein
and Klein, 1964), and the Wild M20 dual
illuminator microscope (Wild, Canada) which
employs an interference (FITC 490 + OG/1)
filter with a blue light source derived from
a high intensity halogen lamp (Iodine
Quartz), have all been described previously
(Lewis and Phillips, 1972). Cells giving a
red appearance with discrete apple-green
fluorescent point staining were regarded as
positive, and unstained cells visualized as
red spheres were negative. Diffusely staining
dead cells were excluded. Under these
conditions it wras possible to identify and
further exclude small lymphocytes because
of their size, and plasma cells because of the
characteristic nuclear/cytoplasmic morpho-
logy. In all instances histological sections,
electron micrographs and cytological smears
stained conventionally were prepared and
examined in addition. The serum of 26
patients was also investigated following
either intradermal autoimmunization with
irradiated tumour cells alone (Ikonopisov et
ald., 1970), or in combination with oral BCG
administration (Lewis and Raymond, 1975).
In addition, tumour and sera from 10
patients who had been treated with intra-
venous phytohaemagglutinin alone (Lewis et
al., 1971), or in combination with auto-
immunisation were examined. Finally, a
further 9 malignant melanoma cases were
studied in a similar fashion, and the positive
direct fluorescent staining small lymphocytes
and plasma cells identified and counted.
RESULTS
The fluorescent indices obtained on
direct immunofluorescence are compared
with those obtained by indirect immuno-
fluorescence on the 37 melanoma patients
(see Fig. 1); the dark areas represent the
fluorescent index on the addition of
anti-human gammaglobulin conjugate
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FIG. 1. Anti-membrane antibo(iy levels in two groups of melanoma patients (dotted areas) (measured by indlrect immunofluorescence) with level of antibody on tumour cell surfaces (dark areas) meastured by direct immunofluorescence.
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TABLE I. Comparison Between Autoimmunization and Intravenou-s Phytohaemagglutinin
Production of Serum Antibody and Tumour-bound Antibody in Melanoma Patients
Tmmuniizin-g procelulre
AultoimmonizatioIi wvith or vvithout
subsequent BCG
Intravenous PHA writh oI' xwithout
autoimmunization
Seruim Ab measured
by in(firect I.F.
Positive Negative
17 9
3
Tumour-bound Ab measured
by direct I.F.
P i N
Positive Negative
24
9
alone (direct) and the dotted areas that
after the administration of serum from
the same individual patients (indirect).
The fluorescent index of the tumour cells
prior to administrationi of the serum
bears no relationship to the index re-
corded when serum is added, irrespective
of whether anti-tumour antibody was
present in the serum or not. In previous
reported studies we showed that an
index of 0 3 or less gave a weak or un-
recordable intensity of fluorescence using
a semiquantitative comparator system
and a quantitative immunofluorescence
microscope (Lewis et al., 1973a). In
none of the 37 cases examined does the
index exceed this figure and in many
was less than 0.10 (Fig. 1). In 24 of
the 26 autoimmunized cases the index
was lower than 0-3 on direct fluorescenice
testing, while in 17 of the 26 cases the
index was greater than 0-3 on indirect
immunofluorescent testing with serum
taken after immunization (see Table I).
Of the 10 cases who were treated with
intri-avenous phytohaemagglutinin, 9 had
significant nulmbers of sta,ined tumour
cells oni direct inmmunofluiorescence, imply-
ing that when antibody is present in
tunlmour cells it can be detected using ouir
methods.
On comparing the fluiorescent index
of ttumour cells to that of the host cells
using direct immunofluorescence, in 9
cases the index of tumour cells again
never exceeded 0-3, while in 4 instances
it was above 0 3 for the host cells (Table
II). Figure 2 shows examples of host
cells with positive immunofluorescence
on application of FITC or peroxidase-
conjugated anti-human gamma globulin.
TABLE II. Comparison Between Immuno-
globulin on Surface of Tumour Cells and
Host CellsafterApplicationofFluorescent
Conjugated Anti-human Gammaglobulin
in Cell Suspensions from NVine Melano-
mata
Patient
PYK
Sz
KT
jP
PA
PE
CH
TH
FL
Tutmour cell
Fltuorescence index
(direct I.F.)
0O01
0O01
0-01
0 00
0 05
0 30
0-I8
0O10
0O00
Host cell
Fluoresc-unce ind(lex
(direct I.F.)
0-65
0-10
0-10
005
0-20
0 40
0 30
0-80
0 25
Much of this immunoglobulin is likely
to be unrelated to tumour antibody and
merely represents normal lymphoid cells
in the area of the tumour. It would,
however, still give positive gammaglobulin
on elution of such a tumour-host cell
mixture. This line of investigationi is
being extended to include a more detailed
morphological and functional examina-
tion of the host cell types and will be
the subject of a further communication.
DISCUSSION
Although there have been several
puiblications showing the presence of
anti-tumour antibody within tumours
(Witz, 1973; Romsdahl and Cox, 1971;
Ran and Witz, 1970), few of these reports
have demonstrated that the antibody
was attached to the surface of the tumour
cells per se. In those iinstances where
this was definitively shown to be true,
the tumours studied were either lymphoid
in origin (Klein et al., 1969; Witz, Klein
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FIG. 2.-Examples of host cells in tumour showing positive immunoglobulin with application of fluorescein-conjugated anti-human gammaglobulin or peroxidase-labelled anti-human gamma- globulin.
(a) Lymphocytes: demonstrating " polar capping" x 2000.
(b) Plasma cell with intracytoplasmic immunoglobulin in a fixed cell smear x 1200.
(c) Macrophage with immunoglobulin and engulfed particles x 1200.
(d) Negative tumour cell and adjacent lymphocyte shows positive reaction with peroxidase- labelled anti-human gammaglobulin x 2000.
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and Pressman, 1969; Nishioka, 1971), or
in the case of solid tumours, lymph node
metastases (Morton, Eilber andMalmgren,
1971) or malignant effusions (Sjogren et al.,
1972; Witz, 1973; Ghose et al., 1972). In
all such cases, serum antibody might be
expected to have reasonable access to the
tumour cells. There is no reason to suppose
that this would necessarily hold for the
more common situation of solid tumour
deposits lying outside the lymphatic or
blood vascular systems.
The concept that a tumour will act
as a sponge, soaking up antibody from
the circulation, has been supported by
the finding that removal of most of the
total tumour mass in man (Morton et
al., 1971; Pilch and Riggins, 1966) and
in animals (Witz, 1973), leads to a rise
in antibody titres. An equally strong
argument can be mounted, however,
without considering the possibility of
antibody reaching the tumour at all,
namely that tumours release soluble
antigen into the circulation and that this
could be expected to complex with any
free antibody already present. Removal
of a tumour would naturally cause a
dramatic drop in the levels of circulating
antigen and antibody would become
detectable; indeed, this has been demon-
strated experimentally with a rat sarcoma
system by Thomson et al. (1973a). Neither
of these concepts constitutes a complete
explanation, as we have shown previously
(Lewis et al., 1973b) and more recently
Bodurtha et al. (1975), that the presence
or absence of circulating antibody in
melanoma patienits cannot be related to
the tumour burden at the time.
It has been suggested by Hall (1969)
that immunoglobulin has an important
role in aiding the maintenance of the
osmotic equilibrium of the blood and
as such would not be expected to leave
the circulation under normal conditions
where the vascular permeability has not
been deranged. It is known, however,
that tumour vessels are not normal,
particularly in relation to their relative
lack of elastica when compared to normal
vessels. Nevertheless, as suggested by
Hall (1969) the concept that certain
forms of cellular immunity are required
in order to carry antibody to sites of
antigenic challenge outside the vasculature
is attractive. In the case of dental
cysts which contain highlevels ofimmuno-
globulin in the lumen, this has been
related to migration of plasma cells
through the cyst walls (Toller and Hol-
borow, 1969). In keeping with this
report are the further reports that IgM,
IgA and IgG were identified in the plasma
cells and small lymphocytes infiltrating
the tumour substance of bladder carcino-
mata (Johansson and Ljungqvist, 1974),
while in the case of breast carcinoma the
amount of immunoglobulin eluted from
the tumours, was related quantitatively
to the number of plasma cells present
within them (Roberts et al., 1973).
Our preliminary investigations of im-
munoglobulin on host cells support the
above reports. Further, our finding of
an extremely low level of positively
staining tumour cells by direct immuno-
fluorescence confirm those ofKopf, Silber-
bergandCooper (1966), whofailedto detect
antibody on the surface of malignant
melanoma, and Thomson, Steele and Alex-
ander (1973b), who found no immunoglob-
ulin on the surface of rat sarcoma cells.
Xenogeneic labelled anti-tumour anti-
sera injected into the circulation have
been shown to localize in the tumour
against which it was raised (Ghose et
al., 1972). Pressman (1966) noted that
this localization occurred in the vascular
bed ofthe target tissue. In other reports,
there is a definite lag period before
localization occurs, ranging from 36 h
to more than 2 days. These findings
would not support the tumour sponge
concept, and it is tempting to speculate
that host cells might be responsible for
carrying antibody into the tumour. In
recent, more definitive experiments on
the rat sarcoma model. no immuno-
globulin is detected on the tumour cells
of both lymphocyte and macrophage
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separation of single cell tumour suspen-
sions (Haskill, Proctor and Yamamura,
1975).
More importantly, results reported in
the present study in which tumour cells
were found to be heavily coated with
immunoglobulin following injection of
phytohaemagglutinin to the patient, serve
to illustrate that if immunoglobulin is
present in reasonable quantities on the
tumour cell surface, it is readily identifi-
able using the techniques we have de-
scribed. We do not have a ready ex-
planation for why this occurred and the
study was stimulated originally by the
observation that in the case of the single
patient treated with intravenous phyto-
haemagglutinin a dramatic regression of
multiple subcutaneous tumour nodules
occurred (Lewis et al., 1971). The tumour
cells within these nodules were found to
be heavily coated with immunoglobulin
while in the case of those removed prior
to administration of PHA there was no
significant staining of tumour cells on
direct fluorescence irrespective of whether
antibody could be detected in the serum
or not.
While the question as to exactly
where immunoglobulin is located within
extravascular tumour deposits must re-
main incompletely answered, it is clear
that (in the presence of serum anti-
tumour antibodies) except under special
circumstances, immunoglobulin would not
appear to be bound to the malignant
melanoma tumour cell surface and that
it is present on host cells. Certainly,
the concept that antibody can act as a
blocking agent to cellular immunity at
the target cell level would seem to be
unlikely, though complexing of free anti-
body with antigen within tumours could
still constitute a valid mechanism for
abrogation of cell-mediated immune
responses within tumours.
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